Addressing Antibiotic Resistance in Women’s Health: The Potential of Vlisse™ by COOLOGICS

Antibiotic resistance is a mounting global health concern. The World Health Organization (WHO) reports a significant increase in drug-resistant infections, highlighting the demand for innovative solutions. This challenge is especially alarming in women’s health. A study analyzing antimicrobial resistance patterns in vaginal swab samples from 2019 to 2022 shows an increasing resistance among vaginal pathogens, making it more challenging to manage these infections with standard treatments.

COOLOGICS, a clinical-stage medical device company, recognizes this concern. It seeks to help reduce the unnecessary use and overuse of antibiotics in treating common vaginal infections by developing impactful solutions. One of its most promising advancements is Vlisse™, a non-drug treatment that intends to address yeast and bacterial vaginal infections through controlled cooling technology.

COOLOGICS acknowledges that in medical practice, antibiotics are typically the first-line treatment for bacterial infections, including bacterial vaginosis (BV), and antifungal drugs are the first-line treatment for yeast infections. Healthcare professionals favor antibiotics due to their broad-spectrum efficacy, however, their efficacy is waning due to drug resistance. Patients also tend to prefer antibiotic treatments because they have been so readily prescribed.

Kimberly Langdon, MD, founder of COOLOGICS, stresses that although effective, antibiotics present disadvantages when used to treat vaginal infections. “Because broad-spectrum antibiotics target all types of pathogens, they often disrupt the natural balance of the vaginal microbiome by killing the good bacteria (Lactobacillus). This can lead to recurrent infections.”

Dr. Langdon is an obstetrician/gynecologist with 19 years of clinical experience. She has dedicated her career to advancing women’s health because of her experience with recurrent yeast infections and the premature birth of her first child at 31 weeks of gestation. Determined to bridge a gap, she made it her mission to develop alternative treatments.

Dr. Langdon observed that many of the conventional treatments available at the time either aggravated symptoms or took too long to work. She then tried to use cold packs externally to help alleviate discomfort. This simple yet effective remedy led her to explore the science behind cooling and its effects on vaginal infections. “I learned that cooling Candida albicans (the most common cause of yeast infections) below a certain temperature could force it into a dormant state, thus stopping the infection,” she shares. This discovery led to the creation of Vlisse™.

Vlisse™ is an intravaginal cooling device designed to provide immediate symptom relief for yeast and bacterial vaginal infections without relying on pharmaceuticals. The device is stored in a freezer for approximately two hours before use. It’s then inserted into the vagina (similar to a tampon) and left in place for about 30 minutes. This controlled cooling process effectively alleviates symptoms and addresses the infection at its source.

The effectiveness of Vlisse™ is based on four key mechanisms of action. First, it cools the infected area to a temperature that forces Candida albicans and certain bacterial pathogens into a dormant state. Second, the cooling effect helps to alleviate inflammation, which is one of the primary causes of discomfort linked to vaginal infections.

Inflammation leads to symptoms like itching, burning, and swelling. Traditional antifungal and antibiotic treatments may take hours or even days to provide relief. Meanwhile, Vlisse™ is developed to offer a near-immediate reduction in these symptoms.

Third, the cooling mechanism has the potential to promote the growth of lactobacillus, the beneficial bacteria that help maintain a healthy vaginal microbiome. Vlisse™ could contribute to a more balanced and resilient vaginal ecosystem by creating an environment conducive to these protective bacteria.

The device may also disrupt biofilms (protective layers formed by bacteria) that contribute to infection recurrence. Biofilms make infections more difficult to treat. Vlisse™ can address this challenge by breaking down these protective barriers.

Vlisse™ is poised to become an alternative to traditional treatments. A clinical study has shown promising results, with many women successfully using Vlisse™ for yeast, bacterial, or mixed vaginal infections. Animal studies have also demonstrated positive outcomes.

Ultimately, the increasing prevalence of antibiotic resistance calls for innovative, non-drug treatment options for common infections. Vlisse™ shows immense potential in providing immediate symptom relief, halting infection progression, and supporting a healthy vaginal microbiome.